在使用基于MRI的放射学进行化学放射治疗后,对局部晚期宫癌的无进展生存预测
1Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA; Advanced Imaging and Informatics for Radiation Therapy Laboratory and Medical Artificial Intelligence and Automation Laboratory, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Clinical oncology (Royal College of Radiologists (Great Britain))
|December 20, 2024
概括
使用MRI T2WI图像的新放射学模型可以在化学放射治疗 (CRT) 后预测局部晚期宫癌 (LACC) 患者的疾病进展. 这种先进的成像生物标志物改进了现有的临床变量,用于个性化治疗策略.
科学领域:
- 在瘤学瘤学.
- 放射学 放射学是一门学科.
- 医疗成像医学成像
背景情况:
- 当地晚期宫癌 (LACC) 患者在化疗放射治疗 (CRT) 后经常经历疾病进展.
- 目前的临床变量不足以准确预测LACC的治疗反应.
- 需要改进的预后工具来指导个性化管理策略.
研究的目的:
- 开发和验证基于放射学的模型,以预测接受CRT的LACC患者的无进展生存期 (PFS).
- 与单独的临床变量相比,评估联合放射学-临床模型的性能.
主要方法:
- 从105名LACC患者的治疗前MR T2加权图像 (T2WI) 中提取了放射性特征.
- 考克斯的比例危险模型和特征选择方法确定了最佳预测因素.
- 一个放射学-临床组合模型被开发并使用嵌套的5倍交叉验证进行验证.
主要成果:
- 来自MR T2WI的放射性特征显著预测了CRT后LACC患者的PFS.
- 与单独的临床变量 (C指数0.655) 相比,联合放射学-临床模型显示出更高的性能 (C指数0.748).
- 该模型有效地将患者分为患病进展高风险和低风险组 (P < 0.001).
结论:
- 一个基于MR T2WI的放射学和临床组合模型为使用CRT治疗的LACC患者预测PFS提供了增强的预后能力.
- 这种放射学方法在LACC中显示出作为个性化治疗策略的成像生物标记物的前景.
- 这些发现支持将MR T2WI放射学纳入LACC管理的临床决策.
更多相关视频
08:12Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
Published on: March 14, 2019
5.4K
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
相关概念视频
01:21Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
02:07Tumor Progression
6.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.2K